Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc. (NASDAQ:IPSC), filed a Form 4 on September 15, 2026, disclosing the automatic sale of 2,587 shares of common stock on September 14, 2026, to cover tax withholding obligations tied to the vesting of restricted stock units.

Key Highlights

  • Shares sold: 2,587 shares of Century Therapeutics common stock were disposed of on September 14, 2026.
  • Sale price: Shares were sold at $1.93 per share.
  • Reason for sale: The filing states the sales were automatic and required to cover tax withholding obligations connected to the vesting of restricted stock units, and were "not at the discretion of the Reporting Person."
  • Direct ownership after transaction: Russotti directly holds 509,198 shares of common stock following the reported transaction.
  • Indirect ownership: Russotti also holds 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust.
  • Signatory: The form was signed by Douglas Carr as Attorney-in-Fact on September 15, 2026.

Gregory Russotti RSU Vesting and Automatic Tax-Withholding Sale at Century Therapeutics

According to the filing, Gregory Russotti, who serves as Chief Technology and Manufacturing Officer of Century Therapeutics, Inc., disposed of 2,587 shares of common stock on September 14, 2026, at a price of $1.93 per share. The filing's footnote specifies that these sales "represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units," and that such sales were automatic and not at Russotti's discretion.

Following the reported transaction, Russotti directly holds 509,198 shares of Century Therapeutics common stock, the filing disclosed. In addition, 92,773 shares are held indirectly through the Gregory Russotti 2021 Family Trust. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed with the Securities and Exchange Commission on September 15, 2026, and was signed by Douglas Carr as Attorney-in-Fact on behalf of the reporting person. The issuer is identified in the filing as Century Therapeutics, Inc., listed on NASDAQ:IPSC.

What Was Disclosed

The filing disclosed an automatic sale of 2,587 common shares at $1.93 per share by Century Therapeutics' Chief Technology and Manufacturing Officer to satisfy tax withholding requirements upon RSU vesting, leaving him with 509,198 shares held directly and 92,773 shares held indirectly.